Neuroprotection after status epilepticus by targeting protein interactions with postsynaptic density protein 95

Journal of Neuropathology and Experimental Neurology

Volumn 68, Issue 7, 2009, Pages 823-831

  Dykstra, Crystal M ^a   Ratnam, Melanie ^a   Gurd, James W ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Epilepsy; N methyl D aspartate receptor; Neuroprotection; Pilocarpine; Status epilepticus.

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEURON SPECIFIC NUCLEAR PROTEIN; NEUROPROTECTIVE AGENT; PILOCARPINE; POSTSYNAPTIC DENSITY PROTEIN 95; TAT N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B 9C; UNCLASSIFIED DRUG; DLGH4 PROTEIN, RAT; HYBRID PROTEIN; MEMBRANE PROTEIN; NERVE PROTEIN; PEPTIDE; SIGNAL PEPTIDE; TAT NR2B9C; TAT-NR2B9C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CELL DENSITY; CELL LOSS; CONTROLLED STUDY; DRUG DOSE COMPARISON; EPILEPTIC STATE; HIPPOCAMPUS; MALE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TARGETING; PYRAMIDAL NERVE CELL; PYRIFORM CORTEX; RAT; SIGNAL TRANSDUCTION; STEREOMETRY; ANIMAL; CELL COUNT; CELL DEATH; CHEMICALLY INDUCED DISORDER; CONFOCAL MICROSCOPY; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; METABOLISM; NERVE DEGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; TIME; WISTAR RAT;

ANIMALS; CELL COUNT; CELL DEATH; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MICROSCOPY, CONFOCAL; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; PEPTIDES; PILOCARPINE; PYRAMIDAL CELLS; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; RECOMBINANT FUSION PROTEINS; STATUS EPILEPTICUS; TIME FACTORS;

EID: 68249157084     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3181ac6b70     Document Type: Article

References (77)

1. DeLorenzo RJ, Hauser WA, Towne AR, et al. A perspective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996;28:10-17
2. Fountain NB. Status epilepticus: Risk factors and complications. Epilepsia 2000;41:23-30
3. Rice AC, Floyd CL, Lyeth DG, et al. Status epilepticus causes long-term NMDA receptor-dependent behavioral changes and cognitive deficits. Epilepsia 1998;39:1148-57
4. Deshpande LS, Lou JK, Mian A, et al. Time course and mechanism of hippocampal neuronal death in an in vitro model of status epilepticus: Role of NMDA receptor activation and NMDA dependent calcium entry. Eur J Pharmacol 2008;1:73-83
5. Fujikawa DG, Itabashi HH, Wu A, et al. Status epilepticus-induced neuronal loss in humans without systemic complications or epilepsy. Epilepsia 2000;41:981-91
6. Cavazos JE, Sutula TP. Progressive neuronal loss induced by kindling: a possible mechanism for mossy fiber synaptic reorganization and hippo-campal sclerosis. Brain Res 1990;527:1-6
7. Nevander G, Ingvar M, Auer R, et al. Status epilepticus in well oxygenated rats causes neuronal necrosis. Ann Neurol 1985;18:281-90
8. Cavalheiro EA, Silva DF, Turski WA, et al. The susceptibility of rats to pilocarpine-induced seizures is age-dependent. Brain Res 1987;37:43-58
9. Turski WA, Czuczwar SJ, Kleinrok Z, et al. Cholinomimetics produce seizures and brain damage in rats. Experientia 1983;39:1408-11 (Pubitemid 14203754)
10. Turski WA, Cavalheiro EA, Schwarz M, et al. Limbic seizures produced by pilocarpine in rats: Behavioural, electroencephalographic and neuro-pathological study. Behav Brain Res 1983;9:315-35
11. Ben-Ari Y. Limbic seizure and brain damage produced by kainic acid: Mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 1985;14:375-404
12. Fujikawa DG, Shinmei SS, Cai B. Kainic acid-induced seizures produce necrotic, not apoptotic, neurons with internucleosomal DNA cleavage: implications for programmed cell death mechanisms. Neuroscience 2000;98:41-53
13. Clifford DB, Olney JW, Benz AM, et al. Ketamine, phencyclidine, and MK-801 protect against kainic acid-induced seizure-related brain damage. Epilepsia 1990;31:382-90
14. Fariello RG, Golden GT, Smith GG, et al. Potentiation of kainic acid epileptogenicity and sparing from neuronal damage by an NMDA receptor antagonist. Epilepsy Res 1989;3:206-13
15. Fujikawa DG. Neuroprotective effect of ketamine administered after status epilepticus onset. Epilepsia 1995;36:186-95
16. Fujikawa DG, Daniels AH, Kim JS. The competitive NMDA receptor antagonist CGP 40116 protects against status epilepticus-induced neuronal damage. Epilepsy Res 1994;17:207-19
17. Lahti AC, Koffe lB, LaPorte D, et al. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13:9-19
18. Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996;14:301-7
19. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214
20. Rowland LM, Astur RS, Jung RE, et al. Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsycho-pharmacology 2005;30:633-39
21. Olney JW, Labruyere J, Wang G. NMDA antagonist neurotoxicity: Mechanism and prevention. Science 1991;254:1515-18
22. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989;244:1360-62
23. Fix AS, Horn JW, Wightman KA, et al. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-d-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): A light and electron microscopic evaluation of the rat retrosplenial cortex. Exp Neurol 1993;123: 204-15
24. Aarts M, Liu Y, Liu L, et al. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 2002; 298:846-50
25. Sattler R, Xiong Z, Lu WY, et al. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 1999; 284:1845-48
26. Cui H, Hayashi A, Sun H. PDZ Protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. J Neurosci 2007;27:9901-15
27. Sun HS, Doucette TA, Liu YT, et al. Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat. Stroke 2008;39: 2544-53
28. Glien M, Brandt C, Potschka H, et al. Repeated low-dose treatment of rats with pilocarpine: Low mortality but high proportion of rats developing epilepsy. Epilepsy Res 2001;46:111
29. Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972;32:281-94
30. Cammisuli S, Murphy MP, Ikeda-Douglas CJ, et al. Effects of extended electrical kindling on exploratory behavior and spatial learning. Behav Brain Res 1997;89:179-90
31. Kornau H, Schenker LT, Kennedy MB. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science 1995;269:1737-40
32. West MJ, Gunderson HJG. Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol 1990; 296:1-22
33. Shi L, Argenta AE, Winseck AK, et al. Stereological quantification of GAD-67-immunoreactive neurons and boutons in the hippocampus of middle-aged and old Fischer 344 x brown Norway rats. J Comp Neurol 2004;478:282-91
34. Hatton WJ, Von Bartheld CS. Analysis of cell death in the trochlear nucleus of the chick embryo: Calibration of the optical disector counting method reveals systematic bias. J Comp Neurol 1999;409:169-86
35. Azcoitia I, Perez-Martin M, Salazar V, et al. Growth hormone prevents neuronal loss in the aged rat hippocampus. Neurobiol Aging 2005;26: 697-703
36. Harding AJ, Halliday GM, Cullen K. Practical considerations for the use of the optical dissector in estimating neuronal number. J Neurosci Methods 1994;51:83-89
37. Gardella D, Hatton WJ, Rind HB, et al. Differential tissue shrinkage and compression in the z-axis: Implications for optical disector counting in vibratome-, plastic- and cryosections. J Neurosci Methods 2003;124: 45-59
38. Andre V, Dube C, Francois J, et al. Pathogenesis and pharmacology of epilepsy in the lithium-pilocarpine model. Epilepsia 2007;38:41-47
39. Chen S, Kobayashi M, Honda Y, et al. Preferential neuron loss in the rat piriform cortex following pilocarpine-induced status epilepticus. Epilepsy Res 2007;4:1-18
40. Druga R, Kubova H, Suchomelova L, et al. Lithium/pilocarpine status epilepticus-induced neuropathology of piriform cortex and adjoining structures in rats is age-dependent. Physiol Res 2003;52:251-64
41. Clifford DB, Olney JW, Maniotis A, et al. The functional anatomy and pathology of lithium-pilocarpine and high-dose pilocarpine seizures. Neuroscience 1987;23:953-68
42. Covolan L, Mello LE. Temporal profile of neuronal injury following pilocarpine or kainic acid-induced status epilepticus. Epilepsy Res 2000; 39:133-52
43. Fujikawa DG. The temporal evolution of neuronal damage from pilocarpine-induced status epilepticus. Brain Res 1996;725:11-22
44. Davis SM, Lees KR, Albers GW, et al. Selfotel in acute ischemic stroke: Possible neurotoxic effects of an NMDA antagonist. Stroke 2000;31: 347-54
45. Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol 2002; 34:235-44
46. Muir KW. Glutamate-based therapeutic approaches: Clinical trials with NMDA antagonists. Curr Opin Pharmacol 2006;6:53-60
47. Albers GW, Goldstein LB, Hall D, et al. Aptiganel hydrochloride in acute ischemic stroke: A randomized controlled trial. JAMA 2001;286: 2673-83
48. Dyker AG, Edwards KR, Fayad PB, et al. Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke. Stroke 1999;39:2544-53
49. Aarts MM, Tymianski M. Molecular mechanisms underlying specificity of excitotoxic signaling in neurons. Curr Mol Med 2004;4:137-47
50. Arundine M, Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 2003;34: 325-37
51. Forder JP, Tymianski M. Postsynaptic mechanisms of excitotoxicity: Involvement of postsynaptic density proteins, radicals, and oxidant molecules. Neuroscience 2009;158:293-300
52. Gupta RC, Dettbarn W. Prevention of kainic acid seizures-induced changes in levels of nitric oxide and high-energy phosphates by 7-nitroindazole in rat brain regions. Brain Res 2003;981:184-92
53. Montecot C, Rondi-Reig L, Springhetti V, et al. Inhibition of neuronal (type 1) nitric oxide synthase prevents hyperaemia and hippocampal lesions resulting from kainate-induced seizures. Neuroscience 1998;84: 791-800
54. Murashima YL, Yoshii M, Suzuki J. Role of nitric oxide in the epilep-togenesis of EL mice. Epilepsia 2000;41:195-99
55. Sardo P, Ferraro G. Modulatory effects of nitric oxide-active drugs on the anticonvulsant activity of lamotrigine in an experimental model of partial complex epilepsy in the rat. BMC Neurosci 2007;8:47-57
56. Rajasekaran K, Jayakumar R, Venkatachalam K. Increased neuronal nitric oxide synthase (nNOS) activity triggers picrotoxin-induced seizures in rats and evidence for participation of nNOS mechanism in the action of antiepileptic drugs. Brain Res 2003;979:85-97
57. McNamara JO, Huang YZ, Leonard S. Molecular signaling mechanisms underlying epileptogenesis. Sci STKE 2006;356:1-17
58. Lorente De NóR. Studies on the structure of the cerebral cortex. II. Continuation of the study of the ammonic system. J Psychol Neurol 1934;46:113-77
59. Li XG, Somogyi P, Ylinen A, et al. The hippocampal CA3 network: An in-vivo intracellular labeling study. J Compar Neurol 1994;339: 181-208
60. Nakanishi S, Masu M, Bessho Y, et al. Molecular diversity of glutamate receptors and their physiological functions. Experienca 1994;71:71-80
61. Cull-Candy S, Brickley S, Farrant M. NMDA receptor subunits: Diversity, development and diseaes. Curr Opin Neurobiol 2001;11: 327-35
62. Cousins SL, Kenny AV, Stephenson FA. Delineation of additional PSD-95 binding domains within NMDA receptor NR2 subuntis reveals differences between NR2A/PSD-95 and NR2B/PSD-95 association. Neuroscience 2009;158:89-95
63. Cousins SL, Papadakis M, Rutter R, et al. Differential interaction of NMDA receptor subtypes with the post-synaptic density-95 family of membrane associated guanylate kinase proteins. J Neurochem 2008;104: 903-13
64. Al-Hallaq RA, Conrads TP, Veenstra TD, et al. NMDA di-heteromeric receptor populations and associated proteins in rat hippocampus. J Neurosci 2007;27:8334-43
65. Lynch DR, Guttmann RP. Excitotoxicity: Perspectives based on N-methyl-D-aspartate receptor subtypes. J Pharmacol Exp Ther 2002; 300:717-23
66. Coultrap SJ, Nixon KM, Alvestad RM, et al. Differential expression of NMDA receptor subunits and splice variants among the CA1, CA3 and dentate gyrus of the adult rat. Curr Opin Neurobiol 2005;135:104-11
67. Pandis C, Sotiriou E, Kouvaras E, et al. Differential expression of NMDA and AMPA receptor subunits in the rat dorsal and ventral hippocampus. Neurosci 2006;140:163-75
68. Papatheodoropoulos C. NMDA receptor-dependent high-frequency network oscillations (100-300 Hz) in rat hippocampal slices. Neurosci Lett 2007;414:197-202
69. Niimura M, Moussa R, Bissoon N, et al. Changes in phosphorylation of the NMDA receptor in the rat hippocampus induced by status epilepticus. J Neurochem 2005;92:1377-85
70. Wyneken U, Smalla KH, Marengo JJ, et al. Kainate-induced seizures alter protein composition and N-methyl-d-aspartate receptor function of rat forebrain postsynaptic densities. Neuroscience 2001;102:65-74
71. Huo JZ, Dykstra CM, Gurd JW. Increase in tyrosine phosphorylation of the NMDA receptor following the induction of status epilepticus. Neurosci Lett 2006;401:266-70
72. Moussa RC, Ikeda-Douglas CJ, Thakur V, et al. Seizure activity results in increased tyrosine phosphorylation of the N-methyl-D-aspartate receptor in the hippocampus. Mol Brain Res 2001;95:36-47
73. Schwarze SR, Ho A, Vocero-Akbani A, et al. In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 1999;285:1569-72
74. Fabene PF, Navarro MG, Martinello M, et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med 2008;14: 1377-83
75. van Vliet EA, da Costa Araujo S, Redeker S, et al. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 2007; 130:521-34
76. Fabene PF, Mora GN, Martinello M, et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med 2008;14:1377-83
77. Brandt C, Gastens AM, Sun MZ, et al. Treatment with valproate after status epilepticus: Effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. Neuropharmacology 2006;51:789-804